Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) Financial Performance & Income Statement Overview
Explore the financials of Ligand Pharmaceuticals Incorporated (LGND), including yearly and quarterly data on income, cash flow, and balance sheets.
Ligand Pharmaceuticals Incorporated (LGND) Income Statement & Financial Overview
Analyze Ligand Pharmaceuticals Incorporated’s LGND earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $45.33M | $42.81M | $51.81M | $41.53M |
| Cost of Revenue | $4.85M | $2.84M | $12.49M | $11.16M |
| Gross Profit | $40.48M | $39.98M | $39.32M | $30.37M |
| Gross Profit Ratio | $0.89 | $0.93 | $0.76 | $0.73 |
| R&D Expenses | $50.09M | $4.42M | $5.67M | $5.35M |
| SG&A Expenses | $18.80M | $25.61M | $24.48M | $17.62M |
| Operating Expenses | $76.70M | $49.61M | $36.17M | $57.73M |
| Total Costs & Expenses | $81.55M | $52.45M | $48.67M | $60.63M |
| Interest Income | $1.77M | $1.93M | $1.35M | $2.76M |
| Interest Expense | $867000.00 | $883000.00 | $741000.00 | $1.27M |
| Depreciation & Amortization | $8.77M | $8.63M | $8.99M | $8.85M |
| EBITDA | -$40.54M | -$29.69M | $3.40M | -$55.27M |
| EBITDA Ratio | -$0.89 | -$0.69 | $0.07 | -$1.33 |
| Operating Income | -$36.22M | -$9.64M | $3.14M | -$19.10M |
| Operating Income Ratio | -$0.80 | -$0.23 | $0.06 | -$0.46 |
| Other Income/Expenses (Net) | -$13.96M | -$29.56M | -$9.48M | -$46.29M |
| Income Before Tax | -$50.18M | -$39.20M | -$6.34M | -$65.39M |
| Income Before Tax Ratio | -$1.11 | -$0.92 | -$0.12 | -$1.57 |
| Income Tax Expense | -$7.73M | -$8.11M | $833000.00 | -$13.48M |
| Net Income | -$42.45M | -$31.09M | -$7.17M | -$51.91M |
| Net Income Ratio | -$0.94 | -$0.73 | -$0.14 | -$1.25 |
| EPS | -$2.21 | -$1.64 | -$0.39 | -$2.88 |
| Diluted EPS | -$2.21 | -$1.64 | -$0.39 | -$2.88 |
| Weighted Avg Shares Outstanding | $19.19M | $18.97M | $18.42M | $18.03M |
| Weighted Avg Shares Outstanding (Diluted) | $19.19M | $18.97M | $18.42M | $18.03M |
Financial performance has remained strong, with revenue growing from $41.53M in Q2 2024 to $45.33M in Q1 2025. Gross profit continued to perform well, with margins at 89% in the latest quarter. Operating income reached -$36.22M in Q1 2025, holding a steady -80% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$40.54M. Net income dropped to -$42.45M, keeping EPS at -$2.21. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan